Skip to content
CancerIndex

Publication

Radium-223 alters the levels of soluble immune regulators in the plasma of patients with metastatic castrate-resistant prostate cancer.

Lunj S, Mistry H, Christodoulou T, Smith Tad, Song Y, Nightingale H, Patel K, Cutting P, Kelthy M, Greenhalgh M, Reeves Kj, West C, Hoskin P, Honeychurch J, Choudhury A, Biolatti Lv

Cancer treatment and research communicationsSep 17, 2026PMID 42753580doi:10.1016/j.ctarc.2026.101381 Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 19, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260919-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

The approval of Radium 223 (Ra-223) has played an important role in the management of patients with metastatic castrate-resistant prostate cancer (mCRPC) by demonstrating improved symptom control and overall survival. However, not all patients respond, leading to an urgent need to develop…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.